Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 公共衛生學院
  3. 流行病學與預防醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/104530
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor林先和zh_TW
dc.contributor.advisorHsien-Ho Linen
dc.contributor.author翁咏聖zh_TW
dc.contributor.authorYong-Sheng Wongen
dc.date.accessioned2026-08-28T16:09:25Z-
dc.date.available2026-08-29-
dc.date.copyright2026-08-28-
dc.date.issued2026-
dc.date.submitted2026-07-07 00:00:00-
dc.identifier.citation1. World Health Organization. Global tuberculosis report 2025. Geneva (Switzerland): World Health Organization; 2025. Available at: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025. Accessed June 23, 2026.
2. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health. 2021 Dec;9(12):e1679-e1687. doi: 10.1016/S2214-109X(21)00367-3.
3. Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis. 2021 Jul;21(7):984-992. doi: 10.1016/S1473-3099(20)30919-1
4. Nightingale R, Carlin F, Meghji J, McMullen K, Evans D, van der Zalm MM, Anthony MG, Bittencourt M, Byrne A, du Preez K, Coetzee M, Feris C, Goussard P, Hirasen K, Bouwer J, Hoddinott G, Huaman MA, Inglis-Jassiem G, Ivanova O, Karmadwala F, Schaaf HS, Schoeman I, Seddon JA, Sineke T, Solomons R, Thiart M, van Toorn R, Fujiwara PI, Romanowski K, Marais S, Hesseling AC, Johnston J, Allwood B, Muhwa JC, Mortimer K. Post-TB health and wellbeing. Int J Tuberc Lung Dis. 2023 Apr 1;27(4):248-283. doi: 10.5588/ijtld.22.0514.
5. Allwood BW, van der Zalm MM, Amaral AFS, Byrne A, Datta S, Egere U, Evans CA, Evans D, Gray DM, Hoddinott G, Ivanova O, Jones R, Makanda G, Marx FM, Meghji J, Mpagama S, Pasipanodya JG, Rachow A, Schoeman I, Shaw J, Stek C, van Kampen S, von Delft D, Walker NF, Wallis RS, Mortimer K. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis. 2020 Aug 1;24(8):820-828. doi: 10.5588/ijtld.20.0067.
6. Oh J, Kim S, Yim Y, Kim MS; GBD 2023 Global Chronic Respiratory Disease and Covid Collaborators; Hay SI, Il Shin J, Yon DK. Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study. Nat Med. 2026 Jan;32(1):197-223. doi: 10.1038/s41591-025-04077-9.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2026 report. Deer Park (IL): Global Initiative for Chronic Obstructive Lung Disease; 2025. Available at: https://goldcopd.org/2026-gold-report-and-pocket-guide/. Accessed June 23, 2026.
8. Boers E, Barrett M, Su JG, Benjafield AV, Sinha S, Kaye L, Zar HJ, Vuong V, Tellez D, Gondalia R, Rice MB, Nunez CM, Wedzicha JA, Malhotra A. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw Open. 2023 Dec 1;6(12):e2346598. doi: 10.1001/jamanetworkopen.2023.46598.
9. Boers E, Allen A, Barrett M, Benjafield AV, Rice MB, Wedzicha JA, Kaye L, Zar HJ, Sinha S, Ozoh O, Crotty Alexander LE, Malhotra A. Forecasting the Global Economic and Health Burden of COPD From 2025 Through 2050. Chest. 2025 Oct;168(4):880-889. doi: 10.1016/j.chest.2025.03.029.
10. Zavala MJ, Becker GL, Blount RJ. Interrelationships between tuberculosis and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2023 Mar 1;29(2):104-111. doi: 10.1097/MCP.0000000000000938.
11. Gai X, Allwood B, Sun Y. Advances in the awareness of tuberculosis-associated chronic obstructive pulmonary disease. Chin Med J Pulm Crit Care Med. 2024 Oct 18;2(4):250-256. doi: 10.1016/j.pccm.2024.08.008.
12. Bisson GP, Allwood B, Byrne A, Günther G, Khosa C, Navuluri N, Nightingale R, Schoeman I, van der Zalm MM, Meghji J, Auld S. Post-tuberculosis lung disease: a case definition for use in research studies. Lancet Infect Dis. 2025 Nov 10:S1473-3099(25)00548-1. doi: 10.1016/S1473-3099(25)00548-1.
13. Feng J, Hu M, Duan H. Bidirectional Association Between Tuberculosis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. J Clin Med. 2025 Oct 28;14(21):7639. doi: 10.3390/jcm14217639.
14. Fan H, Wu F, Liu J, Zeng W, Zheng S, Tian H, Li H, Yang H, Wang Z, Deng Z, Peng J, Zheng Y, Xiao S, Hu G, Zhou Y, Ran P. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann Transl Med. 2021 Mar;9(5):390. doi: 10.21037/atm-20-4576.
15. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015 Mar;32:138-46. doi: 10.1016/j.ijid.2014.12.016.
16. O'Reilly A, Zenner D, Haldar P, Barnes S, Meghji J, Pareek M. The importance of post-tuberculosis morbidity in high-income countries. Lancet Respir Med. 2025 May;13(5):380-382. doi: 10.1016/S2213-2600(25)00091-8.
17. Wang J, Yu L, Yang Z, Shen P, Sun Y, Shui L, Tang M, Jin M, Chen B, Ge Y, Lin H, Shen Y, Chen K, Martinez L. Development of chronic obstructive pulmonary disease after a tuberculosis episode in a large, population-based cohort from Eastern China. Int J Epidemiol. 2025 Feb 16;54(2):dyae174. doi: 10.1093/ije/dyae174.
18. Zeng Z, Chen H, Shao Z, Guan Y, Zhan Y, Cao X, Li S, Hao X. Associations of prior pulmonary tuberculosis with the incident COPD: a prospective cohort study. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241239455. doi: 10.1177/17534666241239455.
19. Kim T, Choi H, Kim SH, Yang B, Han K, Jung JH, Kim BG, Park DW, Moon JY, Kim SH, Kim TH, Yoon HJ, Shin DW, Lee H. Increased Risk of Incident Chronic Obstructive Pulmonary Disease and Related Hospitalizations in Tuberculosis Survivors: A Population-Based Matched Cohort Study. J Korean Med Sci. 2024 Mar 25;39(11):e105. doi: 10.3346/jkms.2024.39.e105.
20. Basham CA, Karim ME, Cook VJ, Patrick DM, Johnston JC. Post-tuberculosis airway disease: A population-based cohort study of people immigrating to British Columbia, Canada, 1985-2015. EClinicalMedicine. 2021 Feb 26;33:100752. doi: 10.1016/j.eclinm.2021.100752.
21. Lee CH, Lee MC, Lin HH, Shu CC, Wang JY, Lee LN, Chao KM. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS One. 2012;7(5):e37978. doi: 10.1371/journal.pone.0037978.
22. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019 Oct;19(10):1129-1137. doi: 10.1016/S1473-3099(19)30309-3.
23. Hsieh YL, Lu FW, Haneuse S, Cohen T, Menzies NA, Lin HH. The association between pulmonary TB disease and long-term all-cause mortality: A retrospective, matched cohort study in Taiwan. Paper presented at: The Union World Conference on Lung Health; 2024 Nov 12-15; Bali, Indonesia.
24. Wu X, Tsai SP, Tsao CK, Chiu ML, Tsai MK, Lu PJ, Lee JH, Chen CH, Wen C, Chang SS, Hsu CY, Wen CP. Cohort Profile: The Taiwan MJ Cohort: half a million Chinese with repeated health surveillance data. Int J Epidemiol. 2017 Dec 1;46(6):1744-1744g. doi: 10.1093/ije/dyw282.
25. Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, Lai EC. Taiwan's National Health Insurance Research Database: past and future. Clin Epidemiol. 2019 May 3;11:349-358. doi: 10.2147/CLEP.S196293.
26. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005 Nov 15;162(10):1016-23. doi: 10.1093/aje/kwi307.
27. Tyrer F, Bhaskaran K, Rutherford MJ. Immortal time bias for life-long conditions in retrospective observational studies using electronic health records. BMC Med Res Methodol. 2022 Mar 27;22(1):86. doi: 10.1186/s12874-022-01581-1.
28. Antunes L, Rippin G, Ralphs E, Luguzis A, Arnold K, Lee H. Choosing an Index Date for Untreated Patients in External Comparator Studies. Drug Saf. 2026 Mar;49(3):313-324. doi: 10.1007/s40264-025-01613-x.
29. Iacus SM, King G, Porro G. Causal inference without balance checking: coarsened exact matching. Political Analysis. 2012 Jan;20(1):1-24. doi:10.1093/pan/mpr013.
30. Taiwan Centers for Disease Control. Taiwan Tuberculosis Control Report 2024. Taipei (Taiwan): Ministry of Health and Welfare; 2025. Available at: https://tbreport.cdc.gov.tw/en/. Accessed June 23, 2026.
31. Núñez I, Matthews AA. Detection bias and the role of negative control outcomes. BMJ Med. 2025 Jun 13;4(1):e001336. doi: 10.1136/bmjmed-2025-001336.
32. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805.
33. MJ Health Research Foundation. Technical report. Taipei (Taiwan): MJ Health Research Foundation; 2016. Available at: https://www.mjhrf.org/en/index.php?action=database&id=6. Accessed June 23, 2026.
34. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312.
35. Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag. 2006;14:1–22. doi: 10.29805/JHM.200606.0001.
36. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing Risk. J Am Stat Assoc. 1999 Jun;94:496-509. doi: 10.1080/01621459.1999.10474144.
37. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988 Sep;16:1141-1154. doi: 10.1214/aos/1176350951.
38. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum. 1953;9(3):531-41.
39. van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, Dheda K. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010 Jan;35(1):27-33. doi: 10.1183/09031936.00072909.
40. Liao KM, Kuo LT, Lu HY. The Risk of Tuberculosis in Chronic Obstructive Pulmonary Disease Across Different Comorbidities. J Clin Med Res. 2025 Nov 26;17(11):642-652. doi: 10.14740/jocmr6345.
41. Cheng SL, Chan MC, Wang CC, Lin CH, Wang HC, Hsu JY, Hang LW, Chang CJ, Perng DW, Yu CJ. COPD in Taiwan: a National Epidemiology Survey. Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2459-67. doi: 10.2147/COPD.S89672.
42. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017 Aug 15;167(4):268-274. doi: 10.7326/M16-2607.
43. Ho D, Imai K, King G, Stuart E, Greifer N. Coarsened Exact Matching in MatchIt for R. Available at: https://kosukeimai.github.io/MatchIt/reference/method_cem.html. Accessed June 23, 2026.
44. World Medical Association. WMA Declaration of Taipei on ethical considerations regarding health databases and biobanks. Ferney-Voltaire (France): World Medical Association; 2016. Available at: https://www.wma.net/policies-post/wma-declaration-of-taipei-on-ethical-considerations-regarding-health-databases-and-biobanks/. Accessed June 23, 2026.
45. Akalu TY, Clements ACA, Liyew AM, Gilmour B, Murray MB, Alene KA. Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis. EClinicalMedicine. 2024 Oct 21;77:102898. doi: 10.1016/j.eclinm.2024.102898.
46. Maleche-Obimbo E, Odhiambo MA, Njeri L, Mburu M, Jaoko W, Were F, Graham SM. Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: A systematic review and meta-analysis. PLOS Glob Public Health. 2022 Dec 20;2(12):e0000805. doi: 10.1371/journal.pgph.0000805.
47. Amaral AF, Coton S, Kato B, Tan WC, Studnicka M, Janson C, Gislason T, Mannino D, Bateman ED, Buist S, Burney PG; BOLD Collaborative Research Group. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J. 2015 Oct;46(4):1104-12. doi: 10.1183/13993003.02325-2014.
48. Kamenar K, Hossen S, Gupte AN, Siddharthan T, Pollard S, Chowdhury M, Rubinstein AL, Irazola VE, Gutierrez L, Miranda JJ, Bernabe-Ortiz A, Alam D, Kirenga B, Jones RC, van Gemert F, Wise RA, Checkley W. Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. Thorax. 2022 Nov;77(11):1088-1097. doi: 10.1136/thoraxjnl-2020-216500.
49. Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Pertuze J, Victora CG; Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) Team. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J. 2007 Dec;30(6):1180-5. doi: 10.1183/09031936.00083507.
50. Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ. 2016 Apr 27;352:i1981. doi: 10.1136/bmj.i1981.
51. Wang J, Yuan B, Fang Y, Zhao C, Liu J, Xiong K. Post-tuberculosis morbidities and their associated mortality: moving from challenges to solutions. Eur Respir Rev. 2025 Oct 22;34(178):250148. doi: 10.1183/16000617.0148-2025.
52. Gyawali S, López-Cervantes JP, Jõgi NO, Mustafa T, Johannessen A, Janson C, Holm M, Modig L, Cramer C, Gislason T, Svanes C, Shigdel R. Previous tuberculosis infection associated with increased frequency of asthma and respiratory symptoms in a Nordic-Baltic multicentre population study. ERJ Open Res. 2023 May 22;9(3):00011-2023. doi: 10.1183/23120541.00011-2023.
53. Jiang Z, Dai Y, Chang J, Xiang P, Liang Z, Yin Y, Shen Y, Wang R, Qiongda B, Chu H, Li N, Gai X, Liang Y, Sun Y. The Clinical Characteristics, Treatment and Prognosis of Tuberculosis-Associated Chronic Obstructive Pulmonary Disease: A Protocol for a Multicenter Prospective Cohort Study in China. Int J Chron Obstruct Pulmon Dis. 2024 Sep 25;19:2097-2107. doi: 10.2147/COPD.S475451.
54. Ratnakumar S, Hayward SE, Denneny EK, Goldsmith LP, Evans R, Checkley W, Goletti D, Ong CWM, Gotowiec M, Zhu J, Friedland JS, Porter JC. Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis. Lancet Glob Health. 2025 Jun;13(6):e1020-e1029. doi: 10.1016/S2214-109X(25)00105-6.
55. Ivanova O, Hoffmann VS, Lange C, Hoelscher M, Rachow A. Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people. Eur Respir Rev. 2023 Apr 19;32(168):220221. doi: 10.1183/16000617.0221-2022.
56. Chung KP, Chen JY, Lee CH, Wu HD, Wang JY, Lee LN, Yu CJ, Yang PC; TAMI Group. Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics (Sao Paulo). 2011;66(4):549-56. doi: 10.1590/s1807-59322011000400005.
57. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018 Feb 28;27(147):170077. doi: 10.1183/16000617.0077-2017.
58. Auld SC, Barczak AK, Bishai W, Coussens AK, Dewi IMW, Mitini-Nkhoma SC, Muefong C, Naidoo T, Pooran A, Stek C, Steyn AJC, Tezera L, Walker NF. Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium. Am J Respir Crit Care Med. 2024 Oct 15;210(8):979-993. doi: 10.1164/rccm.202402-0374SO.
59. Kayongo A, Nyiro B, Siddharthan T, Kirenga B, Checkley W, Lutaakome Joloba M, Ellner J, Salgame P. Mechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease. Front Cell Infect Microbiol. 2023 Jun 21;13:1146571. doi: 10.3389/fcimb.2023.1146571.
60. Cioboata R, Olteanu M, Mitroi DM, Roșu SM, Tieranu ML, Vlasceanu SG, Neamtu SD, Tieranu EN, Padureanu R, Balteanu MA. Beyond the Lungs: Cardiovascular Risk in COPD Patients with a History of Tuberculosis-A Narrative Review. J Clin Med. 2026 Jan 14;15(2):661. doi: 10.3390/jcm15020661.
61. World Health Organization. Integrated approach to tuberculosis and lung health: Policy brief. Geneva (Switzerland): World Health Organization; 2025. Available at: https://www.who.int/publications/i/item/9789240107526. Accessed June 23, 2026.
62. Lo HY, Yang SL, Chou P, Chuang JH, Chiang CY. Completeness and timeliness of tuberculosis notification in Taiwan. BMC Public Health. 2011 Dec 12;11:915. doi: 10.1186/1471-2458-11-915.
63. Lo HY, Huang YC, Chan PC, Lee CC, Chiang CY. TB notifications among citizens and non-citizens in Taiwan. Int J Tuberc Lung Dis. 2024 Jul 1;28(7):328-334. doi: 10.5588/ijtld.23.0567.
64. King G, Nielsen R. Why Propensity Scores Should Not Be Used for Matching. Political Analysis. 2019 May;27(4):435–54. doi:10.1017/pan.2019.11.
65. Guy D, Karp I, Wilk P, Chin J, Rodrigues G. Propensity score matching versus coarsened exact matching in observational comparative effectiveness research. J Comp Eff Res. 2021 Aug;10(11):939-951. doi: 10.2217/cer-2021-0069.
66. Ripollone JE, Huybrechts KF, Rothman KJ, Ferguson RE, Franklin JM. Evaluating the Utility of Coarsened Exact Matching for Pharmacoepidemiology Using Real and Simulated Claims Data. Am J Epidemiol. 2020 Jun 1;189(6):613-622. doi: 10.1093/aje/kwz268.
67. Ho TW, Ruan SY, Huang CT, Tsai YJ, Lai F, Yu CJ. Validity of ICD9-CM codes to diagnose chronic obstructive pulmonary disease from National Health Insurance claim data in Taiwan. Int J Chron Obstruct Pulmon Dis. 2018 Oct 2;13:3055-3063. doi: 10.2147/COPD.S174265.
68. Chang SP, Lin HH, Lee MR. Validation of ICD-10 coding accuracy for chronic obstructive pulmonary disease (COPD) in the medical records database of National Taiwan University Hospital Hsinchu Branch [master’s thesis]. Taipei (Taiwan): National Taiwan University; 2025.
69. Huang YT, Wei T, Huang YL, Wu YP, Chan KA. Validation of diagnosis codes in healthcare databases in Taiwan, a literature review. Pharmacoepidemiol Drug Saf. 2023 Jul;32(7):795-811. doi: 10.1002/pds.5608.
70. Hsieh CY, Shao SC, Sung SF, Hsieh MH, Tsai DH, Lin SJ, Lai EC. Taiwan's National Health Insurance Research Database (NHIRD): in the Era of Artificial Intelligence, Causal Inference, and Data Security. Clin Epidemiol. 2025 Nov 25;17:967-981. doi: 10.2147/CLEP.S553894.
71. Cheng SL, Li YR, Huang N, Yu CJ, Wang HC, Lin MC, Chiu KC, Hsu WH, Chen CZ, Sheu CC, Perng DW, Lin SH, Yang TM, Lin CB, Kor CT, Lin CH. Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in Taiwan. Int J Chron Obstruct Pulmon Dis. 2021 Oct 18;16:2869-2881. doi: 10.2147/COPD.S329454.
72. National Health Insurance Administration. COPD Pay-for-Performance Program. Taipei (Taiwan): Ministry of Health and Welfare; 2025. Available at: https://www.nhi.gov.tw/ch/lp-2833-1.html. Accessed June 23, 2026.
73. Taiwan Society of Pulmonary and Critical Care Medicine. Guidelines for the treatment of COPD in Taiwan 2023. Taipei (Taiwan): Taiwan Society of Pulmonary and Critical Care Medicine; 2023. Available at: https://www.tspccm.org.tw/media/15048. Accessed June 23, 2026.
74. Taiwan Centers for Disease Control. Taiwan Guidelines for TB Diagnosis & Treatment, 7th Edition. Taipei (Taiwan): Ministry of Health and Welfare; 2022. Available at: https://www.cdc.gov.tw/InfectionReport/Info/oOxXcvrNT72iyZJ4M2ISIg?infoId=9qq_6LqI1gU4k7Ih0D-ipQ. Accessed June 23, 2026.
75. Taiwan Centers for Disease Control. Tuberculosis Control Manual, 4th Edition. Taipei (Taiwan): Ministry of Health and Welfare; 2023. Available at: https://www.cdc.gov.tw/En/InfectionReport/Info/9YUAXbFsmorP5T10V8qvMA?infoId=eRaHlG93X2NSoMwv0Y-rqA. Accessed June 23, 2026.
76. Lai TC, Chiang CY, Wu CF, Yang SL, Liu DP, Chan CC, Lin HH. Ambient air pollution and risk of tuberculosis: a cohort study. Occup Environ Med. 2016 Jan;73(1):56-61. doi: 10.1136/oemed-2015-102995.
77. Guo C, Zhang Z, Lau AKH, Lin CQ, Chuang YC, Chan J, Jiang WK, Tam T, Yeoh EK, Chan TC, Chang LY, Lao XQ. Effect of long-term exposure to fine particulate matter on lung function decline and risk of chronic obstructive pulmonary disease in Taiwan: a longitudinal, cohort study. Lancet Planet Health. 2018 Mar;2(3):e114-e125. doi: 10.1016/S2542-5196(18)30028-7.
78. Chan PC, Chiang CY, Lee PH, Lo HY, Chu PW, Chen JJ, Kato S, Raviglione MCB. Assessing the impact of the TB response in Taiwan - the journey towards ending TB. IJTLD Open. 2025 May 12;2(5):251-259. doi: 10.5588/ijtldopen.25.0103.
79. World Health Organization. Policy brief on tuberculosis-associated disability. Available at: Geneva (Switzerland): World Health Organization; 2023. https://www.who.int/publications/i/item/9789240077799. Accessed June 23, 2026.
80. Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. Respiration. 2021;100(8):751-763. doi: 10.1159/000512531.
81. Yarbrough C, Miller M, Zulu M, Sharp D, Andom AT, Ndayizigiye M, Seung KJ, Sonenthal P. Post-tuberculosis lung disease: Addressing the policy gap. PLOS Glob Public Health. 2024 Sep 5;4(9):e0003560. doi: 10.1371/journal.pgph.0003560.
82. Meghji J, Auld SC, Bisson GP, Khosa C, Masekela R, Navuluri N, Rachow A. Post-tuberculosis lung disease: towards prevention, diagnosis, and care. Lancet Respir Med. 2025 May;13(5):460-472. doi: 10.1016/S2213-2600(24)00429-6.
83. Alene KA, Hertzog L, Gilmour B, Clements ACA, Murray MB. Interventions to prevent post-tuberculosis sequelae: a systematic review and meta-analysis. EClinicalMedicine. 2024 Feb 26;70:102511. doi: 10.1016/j.eclinm.2024.102511.
84. Castellana G, Castellana M, Castellana C, Castellana G, Resta E, Carone M, Resta O. Inhaled Corticosteroids And Risk Of Tuberculosis In Patients With Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies. Int J Chron Obstruct Pulmon Dis. 2019 Sep 26;14:2219-2227. doi: 10.2147/COPD.S209273.
85. Byrne A, Allwood B, Schoeman I, Johnston J, Kalyatanda G, Makanda G, Mortimer K, Mitnick C, Nightingale R, Ozoh O, Rachow A, Van Der Zalm M. "Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials. Eur Respir J. 2023 Sep 9;62(3):2300950. doi: 10.1183/13993003.00950-2023.
-
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/104530-
dc.description.abstract背景:結核病與慢性阻塞性疾病(chronic obstructive pulmonary disease,COPD)皆為全球重大死因,且COPD可能作為結核病最主要的呼吸道後遺症,惟現有文獻普遍來自結核病高負擔國家,且多數缺乏明確的時序關係、客觀的暴露測量,限制了因果推論之可靠性。借助本土大型健康資料庫的長期追蹤,本研究旨在探討既往結核病與COPD之間的關聯性,試圖處理潛在干擾及偏差來源,補充結核後肺部疾病的流行病學證據。

方法:本研究為一項基於臺灣成年人群的回溯性世代研究。利用美兆健檢紀錄,串聯全民健保申報、結核病通報登記與死亡統計資料,並依指標年月、年齡、性別、地區、所得、教育程度及累積吸菸量進行粗化精確配對。於2006年至2022年間,共納入1,932名結核病新發個案,以及133,455名未罹患結核病的非暴露組。以Cox比例風險模型與Fine-Gray次分佈風險模型估計結核病史對COPD的效應,另以廣義線性混合模型分析肺功能重複測量數據。

結果:相較於非暴露組,結核病患者後續存在更高的COPD(23.6 vs. 3.9每千人年,p值< 0.001)及相關住院(5.1 vs. 0.5每千人年,p值< 0.001)發生率。校正吸菸、職業暴露、身體質量指數等關鍵變項後,結核病仍與隨後發生COPD(調整後風險比 = 3.00,95%信賴區間:2.60–3.46)及相關住院(調整後風險比 = 3.09,95%信賴區間:2.29–4.16)風險有關。研究族群約有1%的COPD病例可歸因於先前結核病。即使未曾吸菸或成功完成抗結核治療,仍持續面臨罹病風險。此關聯在基線時未確診氣喘,以及痰塗片或培養陽性、胸部X光呈現空洞病灶的肺結核病人中尤其明顯。本研究亦觀察到過往結核病與氣喘風險增加及肺功能下降的相關性。競爭風險模型、敏感度分析,以及陰性對照設計的一致發現,進一步強化了結果的穩健性。

解釋:在結核病發生率較低的情境下,結核病仍應被視為影響COPD發展的獨立危險因子。為減少結核病所造成的終生健康負擔,除了積極推動結核病防治工作外,建立整全的結核後照護管理模式,同樣具有重要的公共衛生與臨床意義。
zh_TW
dc.description.abstractBackground: Tuberculosis (TB) and chronic obstructive pulmonary disease (COPD) are both leading causes of death worldwide, and COPD may represent a major respiratory sequela of TB. However, existing evidence is predominantly derived from high TB-burden areas and often lacks clear temporality and appropriate exposure measurement, thereby limiting the credibility of causal inference. Leveraging large health databases in Taiwan, this study aimed to investigate the association between TB and subsequent COPD while addressing potential confounding and sources of bias.

Methods: We conducted a retrospective cohort study among participants aged ≥ 20 years from the MJ health examination. Data were linked to Taiwan’s National Health Insurance claims, TB registry, and vital statistics. Coarsened exact matching was performed based on the index time, age, sex, region, income, education level, and cumulative smoking exposure. Between 2006 and 2022, we included 1,932 incident TB cases and 133,455 non-TB individuals. Cox proportional hazards models and Fine-Gray subdistribution hazard models were used to estimate the effect of prior TB on COPD, and generalized linear mixed models were applied to analyze repeated lung function measurements.

Findings: Compared with the unexposed group, individuals with a TB history had higher incidence rates of COPD (23.6 vs. 3.9 per 1,000 person-years, p < 0.001) and COPD-related hospitalization (5.1 vs. 0.5 per 1,000 person-years, p < 0.001). After adjustment for smoking and other key covariates, prior TB remained significantly associated with an increased risk of developing COPD (adjusted hazard ratio [aHR] = 3.00, 95% CI: 2.60–3.46) and experiencing COPD-related hospitalizations (aHR = 3.09, 95% CI: 2.29–4.16). Approximately 1% of COPD cases were attributable to previous TB exposure. The elevated risk persisted among never-smokers and patients who had been successfully treated for TB. The association was evident in participants without asthma at baseline and those with smear- or culture-positive pulmonary TB or cavitary lesions on chest X-ray. TB was also associated with potential asthma risk and impaired lung function. The consistency of findings across competing risks, sensitivity analyses, and negative control design further supports the robustness of our results.

Interpretation: Even in a relatively low TB-incidence setting, TB should be considered an independent risk factor for COPD development and clinically relevant outcomes. In addition to strengthening TB control strategies, establishing holistic post-TB care and long-term health management is imperative to reduce the lifetime disease burden among TB survivors.
en
dc.description.provenanceSubmitted by admin ntu (admin@lib.ntu.edu.tw) on 2026-08-28T16:09:24Z
No. of bitstreams: 0
en
dc.description.provenanceMade available in DSpace on 2026-08-28T16:09:25Z (GMT). No. of bitstreams: 0en
dc.description.tableofcontentsMaster’s thesis acceptance certificate 1
Acknowledgements i
摘要 ii
Abstract iv
Table of contents vii
List of figures x
List of tables xi
List of supplementary figures xii
List of supplementary tables xiii
Chapter 1 Introduction xiii
1.1 Background 1
1.2 Literature review 2
1.3 Objectives 4
Chapter 2 Methods 5
2.1 Data sources 5
2.1.1 MJ Health Database 5
2.1.2 National Health Insurance Research Database 5
2.2 Study population 6
2.3 Exposure 8
2.4 Outcome 9
2.4.1 Incident COPD and COPD-related hospitalization 9
2.4.2 Longitudinal lung function changes 9
2.5 Covariates 10
2.5.1 Sociodemographic characteristics 10
2.5.2 Lifestyle behaviors and occupational exposures 11
2.5.3 Biometrics 11
2.5.4 Comorbidities 12
2.6 Statistical analysis 12
2.6.1 Baseline characteristics 12
2.6.2 Survival analysis 13
2.6.3 Repeated measures analysis 15
2.7 Ethics and disclosure 16
Chapter 3 Results 18
3.1 COPD development 18
3.1.1 Baseline characteristics 18
3.1.2 Incident COPD 21
3.1.3 COPD-related hospitalization 23
3.2 Longitudinal lung function changes 31
Chapter 4 Discussion 33
4.1 Key findings 33
4.2 Comparison with previous studies 34
4.3 Biological plausibility 37
4.4 Strengths 38
4.5 Limitations 39
4.6 Clinical and public health implications 43
Chapter 5 Conclusion 45
References 46
Appendix 55
-
dc.language.isoen-
dc.subject結核病-
dc.subject慢性阻塞性肺病-
dc.subject肺功能-
dc.subject結核後肺部疾病-
dc.subject世代研究-
dc.subject臺灣-
dc.subjectTuberculosis-
dc.subjectCOPD-
dc.subjectLung function-
dc.subjectPost-tuberculosis lung disease-
dc.subjectCohort study-
dc.subjectTaiwan-
dc.title結核後慢性阻塞性肺病:以臺灣人群為基礎之回溯性世代研究zh_TW
dc.titlePost-Tuberculosis Chronic Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study in Taiwanen
dc.typeThesis-
dc.date.schoolyear114-2-
dc.description.degree碩士-
dc.contributor.oralexamcommittee郭柏秀;李文宗;詹珮君;王振源zh_TW
dc.contributor.oralexamcommitteePo-Hsiu Kuo;Wen-Chung Lee;Pei-Chun Chan;Jann-Yuan Wangen
dc.subject.keyword結核病; 慢性阻塞性肺病; 肺功能; 結核後肺部疾病; 世代研究; 臺灣zh_TW
dc.subject.keywordTuberculosis; COPD; Lung function; Post-tuberculosis lung disease; Cohort study; Taiwanen
dc.relation.page64-
dc.identifier.doi10.6342/NTU202601710-
dc.rights.note未授權-
dc.date.accepted2026-07-07-
dc.contributor.author-college公共衛生學院-
dc.contributor.author-dept流行病學與預防醫學研究所-
dc.date.embargo-liftN/A-
顯示於系所單位:流行病學與預防醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-114-2.pdf
  未授權公開取用
2.55 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved